Kangstem Biotech Co. Ltd (217730) - Net Assets
Based on the latest financial reports, Kangstem Biotech Co. Ltd (217730) has net assets worth ₩64.83 Billion KRW (≈ $43.93 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩76.42 Billion ≈ $51.79 Million USD) and total liabilities (₩11.60 Billion ≈ $7.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kangstem Biotech Co. Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩64.83 Billion |
| % of Total Assets | 84.82% |
| Annual Growth Rate | 8.2% |
| 5-Year Change | -16.35% |
| 10-Year Change | N/A |
| Growth Volatility | 39.4 |
Kangstem Biotech Co. Ltd - Net Assets Trend (2015–2024)
This chart illustrates how Kangstem Biotech Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 217730 current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Kangstem Biotech Co. Ltd (2015–2024)
The table below shows the annual net assets of Kangstem Biotech Co. Ltd from 2015 to 2024. For live valuation and market cap data, see Kangstem Biotech Co. Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩43.18 Billion ≈ $29.26 Million |
-3.00% |
| 2023-12-31 | ₩44.52 Billion ≈ $30.17 Million |
-5.80% |
| 2022-12-31 | ₩47.26 Billion ≈ $32.03 Million |
-30.57% |
| 2021-12-31 | ₩68.07 Billion ≈ $46.13 Million |
+31.87% |
| 2020-12-31 | ₩51.62 Billion ≈ $34.98 Million |
-27.01% |
| 2019-12-31 | ₩70.72 Billion ≈ $47.93 Million |
+48.29% |
| 2018-12-31 | ₩47.69 Billion ≈ $32.32 Million |
+103.17% |
| 2017-12-31 | ₩23.47 Billion ≈ $15.91 Million |
+2.16% |
| 2016-12-31 | ₩22.98 Billion ≈ $15.57 Million |
+8.19% |
| 2015-12-31 | ₩21.24 Billion ≈ $14.39 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Kangstem Biotech Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15078015748000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩28.03 Billion | 64.90% |
| Other Components | ₩182.04 Billion | 421.57% |
| Total Equity | ₩43.18 Billion | 100.00% |
Kangstem Biotech Co. Ltd Competitors by Market Cap
The table below lists competitors of Kangstem Biotech Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cohen & Steers Real Estate Opportunities and Income Fund
NYSE:RLTY
|
$254.68 Million |
|
INTEKPLUS Co. Ltd
KQ:064290
|
$254.69 Million |
|
Sagar Cements Limited
NSE:SAGCEM
|
$254.76 Million |
|
Millenium Hotels Real Estate I SOCIMI S.A.
MC:YMHRE
|
$254.77 Million |
|
Invalda INVL AB
STU:WTK
|
$254.57 Million |
|
Aekyung Industrial Co Ltd
KO:018250
|
$254.38 Million |
|
SFC Energy AG
XETRA:F3C
|
$254.36 Million |
|
Crescendo Corporation Bhd
KLSE:6718
|
$254.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kangstem Biotech Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 48,011,510,080 to 43,182,021,410, a change of -4,829,488,670 (-10.1%).
- Net loss of 7,669,438,260 reduced equity.
- Share repurchases of 927,630 reduced equity.
- Other factors increased equity by 2,840,877,220.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-7.67 Billion | -17.76% |
| Share Repurchases | ₩927.63K | -0.0% |
| Other Changes | ₩2.84 Billion | +6.58% |
| Total Change | ₩- | -10.06% |
Book Value vs Market Value Analysis
This analysis compares Kangstem Biotech Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.02x to 6.06x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1320.85 | ₩3995.00 | x |
| 2017-12-31 | ₩1180.15 | ₩3995.00 | x |
| 2018-12-31 | ₩2005.29 | ₩3995.00 | x |
| 2019-12-31 | ₩2970.21 | ₩3995.00 | x |
| 2020-12-31 | ₩1819.94 | ₩3995.00 | x |
| 2021-12-31 | ₩1794.32 | ₩3995.00 | x |
| 2022-12-31 | ₩1301.33 | ₩3995.00 | x |
| 2023-12-31 | ₩858.30 | ₩3995.00 | x |
| 2024-12-31 | ₩659.09 | ₩3995.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kangstem Biotech Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -99.01%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.30x
- Recent ROE (-17.76%) is above the historical average (-36.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -27.09% | -387.59% | 0.06x | 1.18x | ₩-7.88 Billion |
| 2016 | -36.12% | -984.85% | 0.02x | 2.06x | ₩-10.60 Billion |
| 2017 | -65.70% | -168.87% | 0.20x | 1.96x | ₩-17.77 Billion |
| 2018 | -28.62% | -148.91% | 0.13x | 1.53x | ₩-18.42 Billion |
| 2019 | -34.83% | -410.26% | 0.05x | 1.61x | ₩-31.71 Billion |
| 2020 | -35.78% | -202.14% | 0.11x | 1.60x | ₩-23.63 Billion |
| 2021 | -31.36% | -172.10% | 0.12x | 1.52x | ₩-28.16 Billion |
| 2022 | -40.99% | -124.14% | 0.20x | 1.63x | ₩-25.17 Billion |
| 2023 | -45.72% | -371.22% | 0.07x | 1.69x | ₩-26.75 Billion |
| 2024 | -17.76% | -99.01% | 0.14x | 1.30x | ₩-11.99 Billion |
Industry Comparison
This section compares Kangstem Biotech Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $368,573,438,392
- Average return on equity (ROE) among peers: 0.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kangstem Biotech Co. Ltd (217730) | ₩64.83 Billion | -27.09% | 0.18x | $254.64 Million |
| ORIENTBIO Inc. (002630) | $57.60 Billion | 0.00% | 0.70x | $43.15 Million |
| Green Cross (005250) | $1.51 Trillion | 0.20% | 0.84x | $425.10 Million |
| Green Cross Holdings Preference Shares (005257) | $1.85 Trillion | 1.30% | 0.98x | $3.74 Million |
| Pharmicell (005690) | $51.52 Billion | 8.44% | 0.23x | $736.42 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $49.94 Million |
| HLB Co. Ltd (028300) | $19.44 Billion | 0.00% | 0.66x | $5.41 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $37.00 Billion | 2.34% | 0.69x | $19.29 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $37.92 Million |
| Hyundai Bioscience Co. Ltd (048410) | $58.24 Billion | 3.27% | 0.77x | $872.13 Million |
| iNtRON Biotechnology Inc (048530) | $11.93 Billion | -9.93% | 0.65x | $77.34 Million |
About Kangstem Biotech Co. Ltd
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease. It also provides stem cell conditioned media, such a… Read more